The vaccine is indicated for pregnant women to provide passive antibodies that protect newborns up to six months of age, and for adults aged 60 and above as active immunisation.

According to Dr. Bach Thi Chinh, medical director of VNVC, RSV has long been recognised by pediatric and respiratory specialists worldwide as a leading cause of pneumonia, bronchitis, bronchiolitis, and severe respiratory failure in infants and the elderly.

In older adults, RSV infection can exacerbate chronic conditions such as cardiovascular disease, liver and kidney disorders, chronic obstructive pulmonary disease (COPD), diabetes, and asthma, significantly increasing hospitalisation and mortality risks.

Pfizer’s RSV vaccine has been approved for use in more than 60 countries, with many including it in their national immunisation programmes for pregnant women and the elderly. This marks the first time a RSV vaccine has become available in Vietnam, giving local residents access to advanced preventive healthcare solutions.

The World Health Organisation (WHO) estimates that RSV causes 3.6 million hospitalisations and about 100,000 deaths annually among children under 5, with nearly 50% of fatalities occurring in infants under 6 months.

In Vietnam, RSV circulates year-round and tends to surge during the rainy season. Each year, hospitals report a high number of pediatric cases of pneumonia and bronchiolitis caused by RSV, including fatalities. Among the elderly, RSV infections often lead to prolonged hospitalisation, intensive care, and a mortality rate of 12–18%.

Health Ministry plans third phase of measles vaccination campaign

VOV.VN - The Ministry of Health (MoH) has requested that the Institutes of Hygiene and Epidemiology and Pasteur Institutes plan the third phase of the measles vaccination campaign this year, focusing on high-risk areas.